Revolution Medicines is a biotechnology company that discovers and develops new medicines for cancer patients by translating frontier oncology targets proteins which drives growth of cancers or that control immune responses that can defeat them.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/revolution-medicines” connections=”true” suffix=””]
Phosphatase Platform is a platform of discovering and developing small molecule inhibitors of protein tyrosine phosphatases (PTPs), enzymes that regulate critical cellular proteins by selectively removing phosphate groups attached to certain tyrosine residues. SHP2 and SHP1 are two main tyrosine phosphotase.
In Apr 2018, Revolution Medicines, Inc., announced of receiving fund worth $56 million in a Series B financing to support its ongoing R&D programs and general business activities. The financing was led by Nextech Invest, including Casdin Capital, Schroder Adveq, The Column Group, Third Rock Ventures and additional undisclosed institutional investors.
In Dec 2016, Revolution Medicines, Inc., announced of receiving $25Mn in a Series A extension financing. The Column Group, joined founding investor Third Rock Ventures. Funding will support the company in its continues advancments and its discovery programs toward clinical development.
In Feb 2015, Third Rock Ventures, LLC financed formation of REVOLUTION Medicines, Inc. with a $45 million Series A financing to discover and develop new therapies derived from natural products.